Description
Trade name:
Lamifen
Compound:
Each tablet contains:
Terbinafine 125 mg
Excipients: hydroxypropyl cellulose, hypromellose, microcrystalline cellulose, silicon dioxide, calcium stearate.
Properties:
Antifungal agent, belongs to the group of aplilamines, has a broad spectrum of antifungal action. In low concentrations it has a fungicidal effect on dermatophytes Trichophyton spp. (Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans, Trichophyton verrucosum, Trichophyton violaceum), Microsporum canis, Epidermophyton floccosum, mold fungi (for example, Scopulariopsis brevicaulis), yeast fungi, mainly Candida albicans. On Candida spp. fungi and their mycelial forms it has a fungicidal or fungistatic effect depending on the type of fungus. Terbinafine disrupts the early stage of biosynthesis of the main component of the fungal cell membrane ergosterol by inhibiting the enzyme squalene epoxidase.
When administered orally, it is not effective in the treatment of pityriasis versicolor caused by Pityrosporum ovale, Pityrosporum orbiculare, Malassezia furfur.
Indications:
Mycoses of the scalp (trichophytosis, microsporia); fungal diseases of the skin and nails (onychomycosis) caused by Trichophyton spp. (T. rubrum, T. mentagrophytes, T. verrucosum, T. violaceum), Microsporum spp. (M. canis, M. gypseum) and Epidermophyton floccosum; severe, widespread dermatomycoses of the smooth skin of the trunk and extremities, requiring systemic treatment; candidiasis of the skin and mucous membranes.
Method of administration and dosage:
Taken orally. The duration of the course of treatment and the dosage regimen are established individually and depend on the localization of the process and the severity of the disease. Adults – at a dose of 250 mg 1 time per day. The course of treatment is 2-6 weeks.
Contraindications:
Acute or chronic liver disease; children under 2 years of age; lactation period; hypersensitivity to terbinafine.
With caution.
Pregnancy; renal failure; alcoholism; suppression of bone marrow hematopoiesis; tumors; metabolic diseases; occlusive diseases of the vessels of the extremities.
Precautions:
Irregular use of terbinafine or premature cessation of treatment may result in relapse of the disease. The duration of therapy may also be affected by such factors as the presence of concomitant diseases, the condition of the nails in onychomycosis at the beginning of the treatment course. If no improvement is observed after 2 weeks of treatment of the skin infection, it is necessary to re-determine the causative agent of the disease and its sensitivity to the drug. Systemic use in onychomycosis is justified only in case of total damage of most nails, the presence of severe subungual hyperkeratosis, and the ineffectiveness of previous local therapy. In the treatment of onychomycosis, a clinical response confirmed by laboratory tests is usually observed several months after mycological cure and cessation of treatment, which is due to the rate of regrowth of a healthy nail. Removal of the nail plates during the treatment of onychomycosis of the hands for 3 weeks and onychomycosis of the feet for 6 weeks is not required. In the presence of liver disease, the clearance of terbinafine may be reduced.
Side effects:
From the central nervous system: often – headache, dizziness.
From the hematopoietic system: very rare (<0.01%) – neutropenia, agranulocytosis, thrombocytopenia.
From the immune system: rarely – anaphylactoid reactions, including angioedema, exacerbation of systemic lupus erythematosus.
From the skin and subcutaneous tissue: often – rash, urticaria; very rarely – psoriasis-like skin rashes, exacerbation of psoriasis, Stevens-Johnson syndrome, toxic epidermal necrolysis, hair loss, acute generalized exanthematous pustulosis.
From the musculoskeletal system: often – arthralgia, myalgia.
General reactions: very rare – fatigue.
Storage method:
At a temperature not exceeding 30 degrees.
Package:
The cardboard box contains 2 blisters of 7 tablets and paper instructions.
